Free tool
FAERS Monitor: Livmarli
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214662 or its brand name (Livmarli, Maralixibat Chloride). Reports on generic versions are filed under their own applications.
Reports
1,002
Serious
284
28% of reports
Hospitalization
158
Death reported
21
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pruritus258
- off label use120
- liver transplant103
- diarrhoea101
- drug ineffective83
- hepatic enzyme increased78
- alanine aminotransferase increased67
- blood bilirubin increased64
- aspartate aminotransferase increased59
- bile acids increased53
- jaundice44
- vomiting41
- product dose omission issue36
- nasopharyngitis34
- abdominal pain32
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 2 |
| 2022 | 336 |
| 2023 | 199 |
| 2024 | 147 |
| 2025 | 163 |
| 2026 | 155 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,157 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| bile acids increasedSignal | 53 | 8980.6 | 6549.7 | 327,115 |
| liver transplantSignal | 103 | 612.0 | 508.2 | 60,473 |
| blood bilirubin increasedSignal | 64 | 49.9 | 39.3 | 3,012 |
| jaundiceSignal | 44 | 34.4 | 25.8 | 1,393 |
| hepatic enzyme increasedSignal | 78 | 24.0 | 19.4 | 1,703 |
| aspartate aminotransferase increasedSignal | 59 | 23.3 | 18.2 | 1,241 |
| alanine aminotransferase increasedSignal | 67 | 22.9 | 18.2 | 1,386 |
| pruritusSignal | 258 | 14.1 | 12.7 | 3,183 |
| nasopharyngitisSignal | 34 | 3.9 | 2.8 | 70 |
| diarrhoeaSignal | 101 | 3.3 | 2.7 | 163 |
| abdominal painSignal | 32 | 2.9 | 2.1 | 38 |
| off label useSignal | 120 | 2.9 | 2.4 | 151 |
| product dose omission issueSignal | 36 | 2.6 | 1.9 | 33 |
| vomiting | 41 | 1.8 | 1.4 | 15 |
| drug ineffective | 83 | 1.3 | 1.1 | 7 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.